A Phase 4 interventional study of Valaciclovir and Placebo in Infections, Herpesviridae, sponsored by GlaxoSmithKline. Completed at 17 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-02-12.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing valacyclovir in Herpes Simplex — none open to participants now, none under way, none of them phase 3. Valacyclovir · Herpes Simplex.
Among the 24 studies testing valacyclovir in Herpes Simplex, this one is the 5th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2005, is one of 5 in phase 4, and was the 9th registered.
166 studies on the registry are indexed under Herpes Simplex; 12 are open to participants now.
Browse Herpes Simplex studies →None of the 24 studies testing valacyclovir in Herpes Simplex is open now. The open studies under Herpes Simplex, anywhere →
Valacyclovir: first FDA approval 1995 (VALTREX). What it is approved for, and how studies give it, is on its page →
Of the 10 Herpes Simplex studies recruiting now, 4 (40%) set no upper age limit and 1 (10%) stops at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 73 is above the median of 66 across 113 interventional studies indexed under Herpes Simplex.
Median enrollment 33 across the 21 interventional studies. Of the 21 that completed or were terminated, 7 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 24 have an industry lead sponsor. The 9 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
20 studies in Herpes Simplex by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 19 finished, 6 (32%) have results posted.
Among the 20 studies in Herpes Simplex by GlaxoSmithKline, this one is the 9th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2005, is one of 2 in phase 4, and was the 7th registered.
GlaxoSmithKline’s Herpes Simplex studies by the year they started, since 1992.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing valacyclovir in Herpes Simplex, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 20 in Herpes Simplex:
This tab as a report to print or save as PDF → With an account.
Eligible subjects will be randomized to receive VALTREX® tablet 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days between treatment periods.
166 studies on the registry are indexed under Herpes Simplex; 12 are open to participants now.
This study's enrollment of 73 is above the median of 66 across 113 interventional studies indexed under Herpes Simplex.
Browse Herpes Simplex studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Compared within Herpes Simplex, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Herpesviridae Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
VALTREX 1 g once daily, Placebo
Drug: Valaciclovir · Drug: Placebo
Placebo, VALTREX 1 g once daily
Drug: Valaciclovir · Drug: Placebo
Valtrex 1g once daily
placebo
Mean Percent Days of Subclinical Shedding as Determined by Type-specific Polymerase Chain Reaction (PCR) Assay for HSV-2
Percent of subclinical days with HSV-2 shedding was defined for each participant as the percent of subclinical days with PCR data for which HSV-2 shedding was detected by a positive PCR result, that is, the number of subclinical days with HSV-2 PCR shedding divided by total number of subclinical days with PCR data, multiplied by 100. For each participant, each study day was classified by PCR as 'shedding' or 'no shedding'; additionally each day was classified as 'clinical' (presence of genital lesions) or subclinical (no genital lesions). Genital/anal-rectal swabs was collected daily during each entire 60-day treatment period of each period and the washout period.
Time frame: Up to Day 60 of each treatment period (up to 160 days)
Mean Percent Days of Total HSV-2 Shedding
The percent of days with total (clinical and subclinical) HSV-2 shedding was defined as the percent of all days with PCR data for which HSV-2 shedding was detected. Mean percent of days with total HSV-2 shedding was the statistic used to summarize this endpoint for each treatment group. For each participant, each study day was classified by PCR as 'shedding' or 'no shedding'; additionally each day was classified as 'clinical' (presence of genital lesions) or 'subclinical" (no genital lesions). The total shedding rate was defined for each participant as the percentage of all days (clinical and subclinical) on treatment during which shedding was detected by PCR. Genital/anal-rectal swabs was collected daily during each entire 60-day treatment period of each period and the washout period.
Time frame: Up to Day 60 of each treatment period (up to 160 days)
Number of Participants With no Shedding
The number of participants with no shedding was defined as the number of participants with no HSV-2 shedding detected by PCR divided by the total number of participants with PCR data. During each 60-day treatment period and during washout, swabs were collected daily from the genital/anal-rectal area for HSV-2 detection by PCR. During an outbreak, lesion swabs were also collected for HSV-2 detection by PCR. For each participant, each study day was classified by PCR as 'shedding' or 'no shedding'; additionally each day was classified as 'clinical' (presence of genital lesions) or 'subclinical" (no genital lesions).
Time frame: Up to Day 60 of each treatment period (up to 160 days)
Mean Log HSV-2 DNA Copy Number Per Day on Days With Subclinical Shedding
The subclinical shedding rate was defined for each participant as the total number of subclinical days on treatment during which shedding was detected by PCR. Average log HSV-2 DNA copy number per day on days with subclinical shedding was defined as the daily maximum HSV-2 DNA copy number was log transformed and averaged over all subclinical shedding days. During each 60-day treatment period and during washout, swabs were collected daily from the genital/anal-rectal area for HSV-2 detection by PCR. During an outbreak, lesion swabs were also collected for HSV-2 detection by PCR. For each participant, each study day was classified by PCR as 'shedding' or 'no shedding'; additionally each day was classified as 'clinical' (presence of genital lesions) or 'subclinical" (no genital lesions).
Time frame: Up to Day 60 of each treatment period (up to 160 days)
Mean Log HSV-2 DNA Copy Number Per Day on Days With Total Shedding
The total shedding rate was defined for each participant as the total number of all days (clinical and subclinical) on treatment during which shedding was detected by PCR. Average log HSV-2 DNA copy number per day on days with total shedding (clinical and subclinical) was defined as the daily maximum HSV-2 DNA copy number was log transformed and averaged over all shedding days. During each 60-day treatment period and during washout, swabs were collected daily from the genital/anal-rectal area for HSV-2 detection by PCR. During an outbreak, lesion swabs were also collected for HSV-2 detection by PCR. For each participant, each study day was classified by PCR as 'shedding' or 'no shedding'; additionally each day was classified as 'clinical' (presence of genital lesions) or 'subclinical" (no genital lesions).
Time frame: Up to Day 60 of each treatment period (up to 160 days)
Percent Overall Study Population Who Have Recognized Clinical Signs/Symptoms of Genital Herpes Infection During the Study
Participants who have recognized clinical signs/symptoms of genital herpes infection during the study. Participants were educated on recognizing signs and symptoms of genital herpes infection at the screening/randomization visit. Genital examinations was conducted at the randomization and genital herpes outbreak visits.
Time frame: Up to Day 60 of each treatment period (up to 160 days)
From March-2005 to January-2006, 73 participants from 13 centers in the United States were randomized into the study (36 in VALTREX™-Placebo, and 37 in Placebo-VALTEX treatment sequence). One participant in each treatment sequence did not receive study medication and intent-to-treat exposed (ITTE) population was comprised of 71 participants.
| Milestone | Sequence 1: VALTREX 1 g Once Daily, Placebo | Sequence 2: Placebo, VALTREX 1 g Once Daily |
|---|---|---|
| Started | 35 | 36 |
| Completed | 28 | 33 |
| Not completed | 7 | 3 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 5 | 0 |
| Withdrew: Other | 1 | 1 |
| Milestone | Sequence 1: VALTREX 1 g Once Daily, Placebo | Sequence 2: Placebo, VALTREX 1 g Once Daily |
|---|---|---|
| Started | 28 | 33 |
| Completed | 28 | 33 |
| Not completed | 0 | 0 |
| Milestone | Sequence 1: VALTREX 1 g Once Daily, Placebo | Sequence 2: Placebo, VALTREX 1 g Once Daily |
|---|---|---|
| Started | 28 | 33 |
| Completed | 24 | 28 |
| Not completed | 4 | 5 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Other | 0 | 2 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
Percent of subclinical days with HSV-2 shedding was defined for each participant as the percent of subclinical days with PCR data for which HSV-2 shedding was detected by a positive PCR result, that is, the number of subclinical days with HSV-2 PCR shedding divided by total number of subclinical days with PCR data, multiplied by 100. For each participant, each study day was classified by PCR as 'shedding' or 'no shedding'; additionally each day was classified as 'clinical' (presence of genital lesions) or subclinical (no genital lesions). Genital/anal-rectal swabs was collected daily during each entire 60-day treatment period of each period and the washout period.
| Percentage of days | VALTREX 1 g Once Daily | Placebo |
|---|---|---|
| Mean Percent Days of Subclinical Shedding as Determined by Type-specific Polymerase Chain Reaction (PCR) Assay for HSV-2 | 1.5 ± 5.3 | 5.1 ± 9 |
The percent of days with total (clinical and subclinical) HSV-2 shedding was defined as the percent of all days with PCR data for which HSV-2 shedding was detected. Mean percent of days with total HSV-2 shedding was the statistic used to summarize this endpoint for each treatment group. For each participant, each study day was classified by PCR as 'shedding' or 'no shedding'; additionally each day was classified as 'clinical' (presence of genital lesions) or 'subclinical" (no genital lesions). The total shedding rate was defined for each participant as the percentage of all days (clinical and subclinical) on treatment during which shedding was detected by PCR. Genital/anal-rectal swabs was collected daily during each entire 60-day treatment period of each period and the washout period.
| Percentage of days | VALTREX 1 g Once Daily | Placebo |
|---|---|---|
| Mean Percent Days of Total HSV-2 Shedding | 1.5 ± 5.2 | 5.5 ± 9.2 |
The number of participants with no shedding was defined as the number of participants with no HSV-2 shedding detected by PCR divided by the total number of participants with PCR data. During each 60-day treatment period and during washout, swabs were collected daily from the genital/anal-rectal area for HSV-2 detection by PCR. During an outbreak, lesion swabs were also collected for HSV-2 detection by PCR. For each participant, each study day was classified by PCR as 'shedding' or 'no shedding'; additionally each day was classified as 'clinical' (presence of genital lesions) or 'subclinical" (no genital lesions).
| Participants | VALTREX 1 g Once Daily | Placebo |
|---|---|---|
| No Shedding | 47 | 30 |
| Shedding | 9 | 26 |
The subclinical shedding rate was defined for each participant as the total number of subclinical days on treatment during which shedding was detected by PCR. Average log HSV-2 DNA copy number per day on days with subclinical shedding was defined as the daily maximum HSV-2 DNA copy number was log transformed and averaged over all subclinical shedding days. During each 60-day treatment period and during washout, swabs were collected daily from the genital/anal-rectal area for HSV-2 detection by PCR. During an outbreak, lesion swabs were also collected for HSV-2 detection by PCR. For each participant, each study day was classified by PCR as 'shedding' or 'no shedding'; additionally each day was classified as 'clinical' (presence of genital lesions) or 'subclinical" (no genital lesions).
| DNA copies per day | VALTREX 1 g Once Daily | Placebo |
|---|---|---|
| Mean Log HSV-2 DNA Copy Number Per Day on Days With Subclinical Shedding | 4.5 ± 0.9 | 4.6 ± 0.4 |
The total shedding rate was defined for each participant as the total number of all days (clinical and subclinical) on treatment during which shedding was detected by PCR. Average log HSV-2 DNA copy number per day on days with total shedding (clinical and subclinical) was defined as the daily maximum HSV-2 DNA copy number was log transformed and averaged over all shedding days. During each 60-day treatment period and during washout, swabs were collected daily from the genital/anal-rectal area for HSV-2 detection by PCR. During an outbreak, lesion swabs were also collected for HSV-2 detection by PCR. For each participant, each study day was classified by PCR as 'shedding' or 'no shedding'; additionally each day was classified as 'clinical' (presence of genital lesions) or 'subclinical" (no genital lesions).
| DNA copies per day | VALTREX 1 g Once Daily | Placebo |
|---|---|---|
| Mean Log HSV-2 DNA Copy Number Per Day on Days With Total Shedding | 4.5 ± 0.9 | 5.2 ± 1.2 |
Participants who have recognized clinical signs/symptoms of genital herpes infection during the study. Participants were educated on recognizing signs and symptoms of genital herpes infection at the screening/randomization visit. Genital examinations was conducted at the randomization and genital herpes outbreak visits.
| Percentage of participants | VALTREX 1 g Once Daily | Placebo |
|---|---|---|
| No Signs/Symptoms | 88 | 77 |
| Signs/symptoms Present | 13 | 23 |
Collected over Adverse events (AE) and serious adverse events (SAE) were reported through out the study (up to 160 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Valtrex 1 g Once Daily | 0/65 (0%) | 0/65 (0%) | 29/65 (44.6%) |
| Placebo | 0/63 (0%) | 1/63 (1.6%) | 42/63 (66.7%) |
| Event | Valtrex 1 g Once Daily | Placebo |
|---|---|---|
| Lower limb fractureInjury, poisoning and procedural complications | 0/65 | 1/63 |
| Loss of consciousnessNervous system disorders | 0/65 | 1/63 |
| Event | Valtrex 1 g Once Daily | Placebo |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 2/65 | 8/63 |
| NasopharyngitisInfections and infestations | 2/65 | 5/63 |
| HeadacheNervous system disorders | 3/65 | 4/63 |
| DizzinessNervous system disorders | 4/65 | 1/63 |
| Vaginitis bacterialInfections and infestations | 1/65 | 3/63 |
| FolliculitisInfections and infestations | 0/65 | 3/63 |
| ToothacheGastrointestinal disorders | 0/65 | 3/63 |
| NauseaGastrointestinal disorders | 3/65 | 1/63 |
| DiarrhoeaGastrointestinal disorders | 2/65 | 2/63 |
| VomitingGastrointestinal disorders | 0/65 | 2/63 |
The ITTE population was defined as consisting of all participants who received at least one dose of investigational product and at least one safety and/or efficacy evaluation.
| Age, Continuous(Years) | Sequence 1: VALTREX 1 g Once Daily, Placebo | Sequence 2: Placebo, VALTREX 1 g Once Daily | Total |
|---|---|---|---|
| Mean | 39.1 ± 12.96 | 35.8 ± 11.69 | 37.4 ± 12.35 |
| Sex: Female, Male(Participants) | Sequence 1: VALTREX 1 g Once Daily, Placebo | Sequence 2: Placebo, VALTREX 1 g Once Daily | Total |
|---|---|---|---|
| Female | 24 | 29 | 53 |
| Male | 11 | 7 | 18 |
| Race (NIH/OMB)(Participants) | Sequence 1: VALTREX 1 g Once Daily, Placebo | Sequence 2: Placebo, VALTREX 1 g Once Daily | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 14 | 19 |
| White | 28 | 19 | 47 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 1 | 0 | 1 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Mar 2005 to primary completion in Jan 2006, 9 months.
Results were first posted in Feb 2018, 12 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valacyclovir